Brokerages expect that Balchem Co. (NASDAQ:BCPC) will post sales of $164.00 million for the current quarter, according to Zacks. Two analysts have made estimates for Balchem’s earnings, with estimates ranging from $157.00 million to $171.00 million. Balchem posted sales of $161.41 million during the same quarter last year, which suggests a positive year over year growth rate of 1.6%. The business is expected to issue its next quarterly earnings results on Friday, May 3rd.

On average, analysts expect that Balchem will report full-year sales of $711.15 million for the current year, with estimates ranging from $660.30 million to $762.00 million. For the next financial year, analysts forecast that the business will post sales of $801.25 million, with estimates ranging from $688.50 million to $914.00 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research firms that follow Balchem.

Balchem (NASDAQ:BCPC) last posted its quarterly earnings results on Thursday, February 28th. The basic materials company reported $0.77 earnings per share for the quarter, beating analysts’ consensus estimates of $0.66 by $0.11. Balchem had a return on equity of 14.59% and a net margin of 12.21%. The business had revenue of $163.50 million for the quarter, compared to analysts’ expectations of $161.42 million. The company’s revenue for the quarter was up 2.6% on a year-over-year basis.

BCPC has been the topic of a number of research analyst reports. Zacks Investment Research cut Balchem from a “hold” rating to a “sell” rating in a research note on Tuesday, December 11th. HC Wainwright set a $101.00 price target on Balchem and gave the company a “buy” rating in a research note on Tuesday, February 5th. BidaskClub cut Balchem from a “sell” rating to a “strong sell” rating in a research note on Wednesday, November 28th. Finally, Seaport Global Securities initiated coverage on Balchem in a research note on Thursday, February 21st. They issued a “neutral” rating on the stock. One research analyst has rated the stock with a sell rating, four have given a hold rating and three have given a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus price target of $105.50.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Advisor Group Inc. grew its holdings in Balchem by 5.5% in the 4th quarter. Advisor Group Inc. now owns 2,470 shares of the basic materials company’s stock valued at $195,000 after buying an additional 128 shares in the last quarter. CIBC Asset Management Inc grew its holdings in Balchem by 7.3% in the 4th quarter. CIBC Asset Management Inc now owns 2,619 shares of the basic materials company’s stock valued at $205,000 after buying an additional 178 shares in the last quarter. Stephens Inc. AR grew its holdings in Balchem by 5.9% in the 4th quarter. Stephens Inc. AR now owns 3,437 shares of the basic materials company’s stock valued at $269,000 after buying an additional 192 shares in the last quarter. State of Alaska Department of Revenue grew its holdings in Balchem by 2.0% in the 4th quarter. State of Alaska Department of Revenue now owns 10,784 shares of the basic materials company’s stock valued at $844,000 after buying an additional 210 shares in the last quarter. Finally, Bank of Montreal Can grew its holdings in Balchem by 13.6% in the 4th quarter. Bank of Montreal Can now owns 1,926 shares of the basic materials company’s stock valued at $151,000 after buying an additional 231 shares in the last quarter. 86.56% of the stock is currently owned by hedge funds and other institutional investors.

BCPC traded down $0.41 during trading hours on Friday, reaching $93.09. The company’s stock had a trading volume of 144,127 shares, compared to its average volume of 117,779. Balchem has a 52 week low of $73.16 and a 52 week high of $117.79. The company has a current ratio of 2.76, a quick ratio of 1.94 and a debt-to-equity ratio of 0.24. The stock has a market cap of $3.01 billion, a PE ratio of 30.93 and a beta of 1.00.

Balchem Company Profile

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the food, nutritional, feed, pharmaceutical, medical sterilization, and industrial markets in the United States and internationally. The company's Human Nutrition & Health segment supplies ingredients in the food and beverage industry.

See Also: What are the Benefits of Index Funds?

Get a free copy of the Zacks research report on Balchem (BCPC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Balchem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Balchem and related companies with MarketBeat.com's FREE daily email newsletter.